Solventum said it entered into a Transaction Agreement with Thermo Fisher Scientific Inc. on February 25, 2025. Thermo Fisher will acquire certain assets and equity interests related to Solventum's purification and filtration business.

1. 01

   Solventum said it entered into a Transaction Agreement with Thermo Fisher Scientific Inc. on February 25, 2025. Thermo Fisher will acquire certain assets and equity interests related to Solventum's purification and filtration business.

2. 02

   Thermo Fisher will pay cash consideration of about $4.10 billion at closing, subject to customary adjustments for closing cash and debt, unpaid transaction expenses and working capital, the company said. The deal also includes the assumption of certain liabilities.

3. 03

   The company said closing is subject to conditions, including the expiration or termination of the Hart-Scott-Rodino waiting period, other antitrust approvals and foreign investment law clearance. Solventum expects to close the transaction by the end of 2025. The Thermo Fisher agreement does not include a financing condition.

4. 04

   The company said the deal may be terminated if it is not closed by November 25, 2025, with two 3-month extensions if only the regulatory closing conditions remain unmet and all other conditions are satisfied. Solventum also agreed to a 3-year non-compete and a 2-year non-solicit and no-hire for certain employees of the business.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.